Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51
Susanne Eder(Intercell (Austria)), Christoph Klade(Intercell (Austria)), Maria Paulke‐Korinek(Medical University of Vienna), Katrin Dubischar-Kastner(Intercell (Austria)), Astrid Kaltenboeck(Intercell (Austria)), Christa Firbas(Medical University of Vienna), Michael Knappik(Helios Klinikum Emil von Behring), Tomáš Jelı́nek(University Hospital Ostrava), Bernd Jilma(Medical University of Vienna), Michael Kundi(Medical University of Vienna), Elisabeth Schuller(Intercell (Austria)), Herwig Kollaritsch(Karl Landsteiner Society)
Cited by 57
Related Papers
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
|The Lancet|2017|3.1k
Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review.
|PubMed|2012|531
EUROPAEM EMF Guideline 2016 for the prevention, diagnosis and treatment of EMF-related health problems and illnesses
|Reviews on Environmental Health|2016|496
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Detoxification of patulin and ochratoxin A, two abundant mycotoxins, by lactic acid bacteria
|Food and Chemical Toxicology|2007|344